Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Development of a neutralization assay for Nipah virus using pseudotype particles.

Tamin A, Harcourt BH, Lo MK, Roth JA, Wolf MC, Lee B, Weingartl H, Audonnet JC, Bellini WJ, Rota PA.

J Virol Methods. 2009 Sep;160(1-2):1-6. doi: 10.1016/j.jviromet.2009.02.025. Epub 2009 Mar 9.

2.

A neutralization test for specific detection of Nipah virus antibodies using pseudotyped vesicular stomatitis virus expressing green fluorescent protein.

Kaku Y, Noguchi A, Marsh GA, McEachern JA, Okutani A, Hotta K, Bazartseren B, Fukushi S, Broder CC, Yamada A, Inoue S, Wang LF.

J Virol Methods. 2009 Sep;160(1-2):7-13. doi: 10.1016/j.jviromet.2009.04.037. Epub 2009 May 9.

PMID:
19433112
3.

Second generation of pseudotype-based serum neutralization assay for Nipah virus antibodies: sensitive and high-throughput analysis utilizing secreted alkaline phosphatase.

Kaku Y, Noguchi A, Marsh GA, Barr JA, Okutani A, Hotta K, Bazartseren B, Fukushi S, Broder CC, Yamada A, Inoue S, Wang LF.

J Virol Methods. 2012 Jan;179(1):226-32. doi: 10.1016/j.jviromet.2011.11.003. Epub 2011 Nov 18.

PMID:
22115786
4.

Rhabdovirus-based vaccine platforms against henipaviruses.

Kurup D, Wirblich C, Feldmann H, Marzi A, Schnell MJ.

J Virol. 2015 Jan;89(1):144-54. doi: 10.1128/JVI.02308-14. Epub 2014 Oct 15.

5.

Efficient reverse genetics reveals genetic determinants of budding and fusogenic differences between Nipah and Hendra viruses and enables real-time monitoring of viral spread in small animal models of henipavirus infection.

Yun T, Park A, Hill TE, Pernet O, Beaty SM, Juelich TL, Smith JK, Zhang L, Wang YE, Vigant F, Gao J, Wu P, Lee B, Freiberg AN.

J Virol. 2015 Jan 15;89(2):1242-53. doi: 10.1128/JVI.02583-14. Epub 2014 Nov 12.

6.

Neutralization assays for differential henipavirus serology using Bio-Plex protein array systems.

Bossart KN, McEachern JA, Hickey AC, Choudhry V, Dimitrov DS, Eaton BT, Wang LF.

J Virol Methods. 2007 Jun;142(1-2):29-40. Epub 2007 Feb 9.

PMID:
17292974
7.

Henipavirus microsphere immuno-assays for detection of antibodies against Hendra virus.

McNabb L, Barr J, Crameri G, Juzva S, Riddell S, Colling A, Boyd V, Broder C, Wang LF, Lunt R.

J Virol Methods. 2014 May;200:22-8. doi: 10.1016/j.jviromet.2014.01.010. Epub 2014 Feb 5.

PMID:
24508193
8.

Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies.

Zhu Z, Dimitrov AS, Bossart KN, Crameri G, Bishop KA, Choudhry V, Mungall BA, Feng YR, Choudhary A, Zhang MY, Feng Y, Wang LF, Xiao X, Eaton BT, Broder CC, Dimitrov DS.

J Virol. 2006 Jan;80(2):891-9.

9.

A functional henipavirus envelope glycoprotein pseudotyped lentivirus assay system.

Khetawat D, Broder CC.

Virol J. 2010 Nov 12;7:312. doi: 10.1186/1743-422X-7-312.

10.

Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody.

Zhu Z, Bossart KN, Bishop KA, Crameri G, Dimitrov AS, McEachern JA, Feng Y, Middleton D, Wang LF, Broder CC, Dimitrov DS.

J Infect Dis. 2008 Mar 15;197(6):846-53. doi: 10.1086/528801.

PMID:
18271743
11.

Induction of neutralizing antibodies to Hendra and Nipah glycoproteins using a Venezuelan equine encephalitis virus in vivo expression system.

Defang GN, Khetawat D, Broder CC, Quinnan GV Jr.

Vaccine. 2010 Dec 16;29(2):212-20. doi: 10.1016/j.vaccine.2010.10.053. Epub 2010 Nov 2.

12.

Protection against henipaviruses in swine requires both, cell-mediated and humoral immune response.

Pickering BS, Hardham JM, Smith G, Weingartl ET, Dominowski PJ, Foss DL, Mwangi D, Broder CC, Roth JA, Weingartl HM.

Vaccine. 2016 Sep 14;34(40):4777-86. doi: 10.1016/j.vaccine.2016.08.028. Epub 2016 Aug 17.

PMID:
27544586
13.

A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge.

Bossart KN, Rockx B, Feldmann F, Brining D, Scott D, LaCasse R, Geisbert JB, Feng YR, Chan YP, Hickey AC, Broder CC, Feldmann H, Geisbert TW.

Sci Transl Med. 2012 Aug 8;4(146):146ra107. doi: 10.1126/scitranslmed.3004241.

14.

Use of monoclonal antibodies against Hendra and Nipah viruses in an antigen capture ELISA.

Chiang CF, Lo MK, Rota PA, Spiropoulou CF, Rollin PE.

Virol J. 2010 Jun 3;7:115. doi: 10.1186/1743-422X-7-115.

15.

Acute Hendra virus infection: Analysis of the pathogenesis and passive antibody protection in the hamster model.

Guillaume V, Wong KT, Looi RY, Georges-Courbot MC, Barrot L, Buckland R, Wild TF, Horvat B.

Virology. 2009 May 10;387(2):459-65. doi: 10.1016/j.virol.2009.03.001. Epub 2009 Mar 28.

16.

Interactions of human complement with virus particles containing the Nipah virus glycoproteins.

Johnson JB, Aguilar HC, Lee B, Parks GD.

J Virol. 2011 Jun;85(12):5940-8. doi: 10.1128/JVI.00193-11. Epub 2011 Mar 30.

17.

Single injection recombinant vesicular stomatitis virus vaccines protect ferrets against lethal Nipah virus disease.

Mire CE, Versteeg KM, Cross RW, Agans KN, Fenton KA, Whitt MA, Geisbert TW.

Virol J. 2013 Dec 13;10:353. doi: 10.1186/1743-422X-10-353.

18.

Single-dose live-attenuated Nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins.

DeBuysscher BL, Scott D, Marzi A, Prescott J, Feldmann H.

Vaccine. 2014 May 7;32(22):2637-44. doi: 10.1016/j.vaccine.2014.02.087. Epub 2014 Mar 12.

19.

Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus.

Bossart KN, Crameri G, Dimitrov AS, Mungall BA, Feng YR, Patch JR, Choudhary A, Wang LF, Eaton BT, Broder CC.

J Virol. 2005 Jun;79(11):6690-702.

20.

Nipah virion entry kinetics, composition, and conformational changes determined by enzymatic virus-like particles and new flow virometry tools.

Landowski M, Dabundo J, Liu Q, Nicola AV, Aguilar HC.

J Virol. 2014 Dec;88(24):14197-206. doi: 10.1128/JVI.01632-14. Epub 2014 Oct 1.

Supplemental Content

Support Center